CYCC Shares Outstanding History
Below is a table of the CYCC shares outstanding history going back to 5/31/2016:

Date CYCC Shares Outstanding

Also see: CYCC Market Cap History
CYCC Historical Shares Outstanding:
+98.74% CAGR
CYCC Historical Shares Outstanding: +98.74% CAGR

Mouse over chart for data details
5/31/2016 ...11/7/2022
Cyclacel Pharmaceuticals is a biopharmaceutical company engaged in developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin Dependent Kinase 2/9 (CDK2/9) inhibitor, in solid tumors and hematological malignancies. CDKs also provide pivotal functions in the regulation of transcription, DNA repair and metastatic spread. The anti-mitotic program is evaluating plogosertib, a polo-like kinase, or PLK inhibitor, in solid tumors and hematological malignancies. PLK1 is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle. We show 29 historical shares outstanding datapoints in our coverage of CYCC's shares outstanding history.

Understanding the changing numbers of CYCC shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like CYCC versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching CYCC by allowing them to research CYCC shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree CYCC Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Cyclacel Pharmaceuticals (CYCC) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

CYCN Shares Outstanding History
CYH Shares Outstanding History
CYRX Shares Outstanding History
CYT Shares Outstanding History
CYTH Shares Outstanding History
CYTK Shares Outstanding History
CYTR Shares Outstanding History
CYTX Shares Outstanding History
DARE Shares Outstanding History
DAWN Shares Outstanding History
More Healthcare companies »


CYCC Shares Outstanding History | | Copyright © 2017 - 2023, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.